BioRestorative Therapies, Inc. — 2012 Form 10-K Summary
Business context and reporting period
This is the company’s annual report for the fiscal year ended December 31, 2012, not a standalone fourth-quarter report. BioRestorative described itself as a development-stage company focused on adult stem-cell therapies, including its ThermoStem brown-fat research program and brtxDISC disc/spine program, alongside early-stage cosmetic products. It reported no significant operating revenue.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $15,589 | $0 |
| Gross profit | $14,282 | $0 |
| Operating expenses | $5,586,734 | $3,552,005 |
| Operating loss | ($5,572,452) | ($3,552,005) |
| Interest expense | $591,813 | $260,011 |
| Net loss | ($6,536,722) | ($4,073,937) |
| Net cash used in operations | $3,184,112 | $2,810,867 |
- 2012 revenue comprised $10,000 of sublicense fees and $5,589 of Stem Pearls skincare sales. The resulting gross margin was approximately 92%, but on very small sales.
- Operating expenses rose about 57%; payroll and benefits increased 43%, consulting expense 169%, and research and development rose to $416,180 from $12,000. Management attributed much of the consulting and payroll growth to non-cash stock compensation and executive compensation.
- Cash was $363 at year-end, versus $71,508 a year earlier. Working capital deficiency was $2,784,676; stockholders’ deficiency was $5,141,693; accumulated development-stage deficit was $14,061,220.
- Year-end gross debt was $4,632,185, with stated interest rates of 8%–15% and maturities through December 2013. Balance-sheet notes payable were reported net of debt discounts. Financing provided $4,115,500 of cash in 2012, while investing used $1,002,533, primarily for the disc/spine license.
- Auditors included a going-concern explanatory paragraph, stating substantial doubt about the company’s ability to continue as a going concern. Management said available cash was expected to fund operations only through May 2013.
Material changes and subsequent financing
Compared with 2011, losses and operating cash use increased, while revenue began at an immaterial level. The company raised $1,925,000 through equity and received $2,265,500 in new debt during 2012. It also exchanged $754,500 of debt for shares and warrants, recording a $69,708 extinguishment loss.
After year-end through March 28, 2013, the company reported $820,000 of equity financing and $450,000 of additional debt. It extended $3,653,500 of debt maturities, including $3,550,000 rolled into a zero-coupon note due July 2014, and exchanged $112,500 of debt for shares and warrants. At filing, management reported approximately $4,970,285 of outstanding debt and $50,000 of notes past due; the filing’s debt schedule separately lists $55,000 as past due/on demand.
Outlook, commentary, and risks
- Management estimated that implementing the brtxDISC program and repaying debt would require approximately $25 million–$50 million, assuming no operating revenue and no debt conversion; other programs would require substantial additional funding. No assurance was given that funding would be available.
- Planned milestones included a brtxDISC pre-IND study expected to finish by the third quarter of 2013, a laboratory expected to begin operations by the fourth quarter of 2013, and ThermoStem preclinical work expected to begin by the first quarter of 2014. The company anticipated clinical trials by the third quarter of 2014. These are projections, not established outcomes.
- Both principal therapeutic programs remained developmental; ThermoStem had no clinical application or product. The company’s ability to proceed depended on financing, research progress, regulatory requirements, and third-party arrangements.
- Regulatory uncertainty is material. A pending FDA case involving the company’s licensor, Regenerative Sciences, could affect the scope of FDA oversight and required approvals; the district court had ruled for the FDA and an appeal was pending.
- Other key risks include continued losses and financing dependence, debt maturity and refinancing risk, potential dilution from equity financing or debt conversions, clinical and scientific uncertainty, competition, intellectual-property protection, and the company’s reliance on key personnel. The company disclosed a pending dispute involving its research executive and former employer.
- The filing reported no legal proceedings involving the company under Item 3, while separately describing the FDA litigation involving its licensor and the employment-related dispute involving its research executive.
Important facts for investors to verify
- Current cash runway, subsequent financing received, remaining past-due obligations, and the complete debt maturity schedule.
- Whether debt extensions and conversions were completed on the terms described, and the resulting dilution and warrant overhang.
- Progress against projected laboratory, preclinical, pre-IND, IND, and clinical-trial milestones, including actual regulatory classification of the proposed therapies.
- Actual commercial revenue, product demand, and economics of the skincare and sublicense businesses.
- Terms, funding obligations, milestones, and royalty provisions in the University of Utah research agreement and the brtxDISC license.
- Developments in the FDA appeal involving Regenerative Sciences and the pending dispute affecting the research executive.